<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-41167" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Opioid-Induced Constipation </title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sizar</surname>
            <given-names>Omeed</given-names>
          </name>
          <aff>St. Lucie Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Genova</surname>
            <given-names>Rafaella</given-names>
          </name>
          <aff>Univ. Tennessee- St Thomas West</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Mohit</given-names>
          </name>
          <aff>Cleveland Clinic Foundation</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Omeed Sizar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rafaella Genova declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohit Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-41167.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Opioid-induced constipation (OIC) accounts for between 40 and sixty percent of patients without cancer receiving opioids. Laxatives must be started at the same time as the opioid to prevent OIC. Once the disorder is established, treatment involves both pharmacological and nonpharmacological therapies. OIC may present immediately when a patient takes the opioid, or it may present gradually during opioid therapy. In association with constipation, patients may also develop other GI side effects like nausea, vomiting, bloat, abdominal pain, and straining. This activity reviews the evaluation and management of opioid induced constipation and explains the role of the interprofessional team in improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the etiology of opioid-induced constipation.</p></list-item><list-item><p>Explain the pathophysiology of opioid-induced constipation.</p></list-item><list-item><p>Explain how to prevent opioid-induced constipation.</p></list-item><list-item><p>Employ well-coordinated, interprofessional team strategies to prevent and treat opioid-induced constipation and improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=41167&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=41167">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-41167.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Opioid-induced&#x000a0;constipation (OIC) accounts&#x000a0;from over 40% to&#x000a0;60% in patients without cancer&#x000a0;receiving opioids<xref ref-type="bibr" rid="article-41167.r1">[1]</xref>.&#x000a0;Laxatives must be started at the same time as the opioid to prevent OIC. Once the disorder is established, treatment involves both pharmacological and nonpharmacological therapies. OIC may present immediately when a patient&#x000a0;takes the opioid, or it may present gradually during opioid therapy. In association with constipation, patients may also develop other GI side effects like nausea, vomiting, bloat, abdominal pain, and straining. Many patients who develop constipation following opioids stop the drug therapy because they simply&#x000a0;cannot tolerate the adverse effects on the GI tract. Once constipation to opioids has developed, the relief with treatment is slow and does not always result in optimal relief from constipation.<xref ref-type="bibr" rid="article-41167.r2">[2]</xref><xref ref-type="bibr" rid="article-41167.r3">[3]</xref><xref ref-type="bibr" rid="article-41167.r4">[4]</xref><xref ref-type="bibr" rid="article-41167.r5">[5]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-41167.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Opioid&#x000a0;drugs are known to inhibit gastric emptying and peristalsis in the GI tract&#x000a0;which results in delayed absorption of medications and increased absorption of fluid. The lack of fluid in the intestine leads to hardening of stool and constipation. Most patients with OIC complain of straining and incomplete emptying of the rectum during defecation. Opioids also increase anal sphincter tone impairing the defecation reflex<xref ref-type="bibr" rid="article-41167.r6">[6]</xref>. Anal sphincter dysfunction is important to note in patients experiencing anal blockage. Moreover, opioids have been found to decrease emptying of pancreatic juice and bile leading to delayed digestion.&#x000a0;</p>
      </sec>
      <sec id="article-41167.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Opioid-induced&#x000a0;constipation (OIC) accounts&#x000a0;from over 40% to&#x000a0;60% in&#x000a0;patients without cancer receiving opioids<xref ref-type="bibr" rid="article-41167.r1">[1]</xref>.&#x000a0;Studies showed that patients who developed OIC were more likely to be older, female, and unemployed.<xref ref-type="bibr" rid="article-41167.r7">[7]</xref><xref ref-type="bibr" rid="article-41167.r8">[8]</xref></p>
      </sec>
      <sec id="article-41167.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The three subclasses of opioid receptors include mu, delta, and kappa. All 3 receptors mediate their actions through coupling with G-protein receptors.<xref ref-type="bibr" rid="article-41167.r9">[9]</xref> In the GI tract, the mu and delta receptors predominate and are found in the myenteric and submucosal plexus. The opioid receptors stimulate the&#x000a0;production of adenylate cyclase and inhibit the calcium channels, which in turn&#x000a0;results in a decrease in neurotransmitter release. Tolerance to opioids not only develops to pain but also to the pharmacological effects on the GI tract.&#x000a0;<xref ref-type="bibr" rid="article-41167.r10">[10]</xref><xref ref-type="bibr" rid="article-41167.r4">[4]</xref><xref ref-type="bibr" rid="article-41167.r11">[11]</xref></p>
      </sec>
      <sec id="article-41167.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Typical symptoms of opioid-induced constipation include&#x000a0;the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Bloated sensation</p>
          </list-item>
          <list-item>
            <p>Constipation</p>
          </list-item>
          <list-item>
            <p>Diarrhea</p>
          </list-item>
          <list-item>
            <p>Nausea, vomiting</p>
          </list-item>
          <list-item>
            <p>Alternating episodes of diarrhea and constipation</p>
          </list-item>
          <list-item>
            <p>Fecal impaction and use of digital evacuation</p>
          </list-item>
          <list-item>
            <p>Poor quality of life</p>
          </list-item>
        </list>
        <p>The physical may reveal mild abdominal distension, and the rectal exam may reveal stool impaction.&#x000a0;</p>
      </sec>
      <sec id="article-41167.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The Rome IV diagnostic criteria is&#x000a0;widely used&#x000a0;for the definition of functional constipation<xref ref-type="bibr" rid="article-41167.r12">[12]</xref>.&#x000a0;</p>
        <p>The Rome<italic toggle="yes">&#x000a0;</italic>IV criteria include&#x000a0;two of following for the last 3 months:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hard stools in at least 25 percent of defecations</p>
          </list-item>
          <list-item>
            <p>Straining in at least 25 percent of defecation</p>
          </list-item>
          <list-item>
            <p>A sensation of incomplete evacuation in at least 25 percent of defecations</p>
          </list-item>
          <list-item>
            <p>Less than 3 bowel movements per week</p>
          </list-item>
          <list-item>
            <p>Use of manual measures to help move or remove the stools from the rectum</p>
          </list-item>
        </list>
        <p>Additionally, the&#x000a0;Bristol Stool Scale can&#x000a0;be used&#x000a0;to&#x000a0;classify the form of feces into seven categories. Type 1 and 2 show hard stools while types 3 and 4 are normal. Individuals with loose stools (types 5 through 7) tend to&#x000a0;have diarrhea.&#x000a0;</p>
        <p>Imaging is not routinely&#x000a0;done when patients present with constipation. Physicians should look out for alarm symptoms including weight loss, positive fecal occult blood tests, iron deficiency anemia, and a family history of colon cancer.</p>
      </sec>
      <sec id="article-41167.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Increasing dietary fiber, fluid intake, and physical exercise are the backbone to prevention therapy. All healthcare workers who prescribe opioids need to also&#x000a0;consider prophylactic treatment for constipation. All&#x000a0;types of laxatives can&#x000a0;be used as&#x000a0;initial therapy except for the bulk-forming laxatives. The annual estimated expenditure for laxatives in the United States is over 800 million dollars <xref ref-type="bibr" rid="article-41167.r13">[13]</xref>. The only laxatives that should be avoided are the bulk-forming laxatives, like psyllium. These laxatives increase the bulk of the stools, distend the colon, and augment peristalsis.&#x000a0;Opioids prevent peristalsis of the increased bulk which worsens abdominal pain and can contribute to bowel obstruction<xref ref-type="bibr" rid="article-41167.r14">[14]</xref>.</p>
        <p>The most common regime for OIC is a stimulant (senna/bisacodyl) with or without a stool softener (docusate), or daily administration of an osmotic laxative (polyethylene glycol). Stool softeners are ideal for preventing constipation; they do not work well for established cases of constipation<xref ref-type="bibr" rid="article-41167.r15">[15]</xref>. Another laxative included saline laxative such as magnesium citrate which has an onset of action from 30 to 180 minutes. For refractory cases of OIC, newer agents may be used with methylnaltrexone being the most superior.</p>
        <p>Methylnaltrexone bromide is the first available peripherally acting opiate antagonist which is used to treat OIC. Methylnaltrexone (Relistor) does not cross the blood-brain barrier which doesn't induce symptoms of opioid withdrawal. Subcutaneous methylnaltrexone was found to be significantly better at reversing OIC than lubiprostone, naloxegol, and oral methylnaltrexone<xref ref-type="bibr" rid="article-41167.r16">[16]</xref>. Relistor should not be used in patients with peptic ulcer disease, diverticulosis, colon cancer, or obstruction<xref ref-type="bibr" rid="article-41167.r17">[17]</xref>.</p>
        <p>Lubiprostone&#x000a0;(Amitiza) is a type-2 chloride channel activator that increases secretion of fluid in the GI tract. These actions result in increased tone, enhanced peristalsis, and increased acceleration of the small bowel and colonic transit times. Studies show that lubiprostone can increase the overall frequency of bowel movements each week in patients with opioid-induced constipation.&#x000a0;<xref ref-type="bibr" rid="article-41167.r18">[18]</xref></p>
        <p>Other therapies include naloxegol, alvimopan, and naldemedine.&#x000a0;Naloxegol&#x000a0;and naldemedine&#x000a0;are both approved for treatment of OIC in patients with non-cancer pain. Alvimopan has only been approved to treat recalcitrant cases of postoperative ileus.<xref ref-type="bibr" rid="article-41167.r19">[19]</xref>&#x000a0;In the United States, lubiprostone is approved for treatment of OIC in patients with non-cancer pain and those with cancer.&#x000a0;</p>
      </sec>
      <sec id="article-41167.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Colonic obstruction&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Crohn's disease</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>diverticulitis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypopituitaris</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypothyroidism</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ileus</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Intestinal motility disorders</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Irritable bowel syndrome</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Large bowel obstruction</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ogilive syndrome</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-41167.s10" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>
<bold>Lifestyle Changes</bold>
</p>
        <p>Whenever an opiate is prescribed, the patient should be educated on the prevention of constipation. This means eating an adequate fiber in the diet, drinking ample water, exercising to encourage motility of the bowels, limiting intake of other painkillers, and using a laxative. Other alternatives instead of milk of magnesia include the&#x000a0;use of docusate or polyethylene glycol. The changes in lifestyle should start at the same time as the opioid therapy and continue for the duration of treatment.</p>
        <p>
<bold>Dietary</bold>
</p>
        <p>There are many fiber-rich foods that one can eat to treat constipation. Fruits like apples, bananas, prunes, pears, raspberries, and vegetables like string beans, broccoli, spinach, kale, squash, lentils, peas, and beans are often recommended. One can also eat almost any type of&#x000a0;bran products (usually cereals) and nuts. When eating foods with fiber, it is important not to consume more than 25 to 30 grams per day otherwise it can lead to a bloating sensation.</p>
      </sec>
      <sec id="article-41167.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Ways to prevent opioid-induced&#x000a0;constipation is by working as an interprofessional team consisting of a nurse, pharmacist, gastroenterologist, and a pain consultant. It is important to manage pain with non-opioid drugs, and the patient must be educated about the adverse effects by the pharmacist and clinician including constipation. The nurse should encourage a diet high in fiber, ample water, and regular exercise. The pharmacist should recommend discontinuation of drugs which cause constipation and suggest other options. If opioids cannot be avoided, a laxative and high fiber diet should be started simultaneously, and the nurse should monitor the patient's bowel habits. The patient's pain should be periodically assessed, and the dose of narcotics decreased gradually. An interprofessional approach to patient education may help prevent this problem and improve outcomes.&#x000a0; <xref ref-type="bibr" rid="article-41167.r20">[20]</xref><xref ref-type="bibr" rid="article-41167.r21">[21]</xref><xref ref-type="bibr" rid="article-41167.r22">[22]</xref></p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>Unfortunately once OIC has developed, returning bowel function to the pre-opiate status is difficult. Even though many novel drug combinations have been developed, no long-term studies are available to determine their effectiveness. Almost all studies suggest that use of non-opiates should be the drugs of first choice to manage pain if one wants to avoid OIC. (Level V)</p>
      </sec>
      <sec id="article-41167.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=41167&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=41167">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/gut-health/opioid-induced-constipation/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=41167">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/41167/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=41167">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-41167.s13">
        <title>References</title>
        <ref id="article-41167.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coyne</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Margolis</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Yeomans</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Chavoshi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Payne</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>LoCasale</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Opioid-Induced Constipation Among Patients with Chronic Noncancer Pain in the United States, Canada, Germany, and the United Kingdom: Laxative Use, Response, and Symptom Burden Over Time.</article-title>
            <source>Pain Med</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>16</volume>
            <issue>8</issue>
            <fpage>1551</fpage>
            <page-range>1551-65</page-range>
            <pub-id pub-id-type="pmid">25802051</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41167.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Imam</surname>
                <given-names>MZ</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ghassabian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression.</article-title>
            <source>Neuropharmacology</source>
            <year>2018</year>
            <month>Mar</month>
            <day>15</day>
            <volume>131</volume>
            <fpage>238</fpage>
            <page-range>238-255</page-range>
            <pub-id pub-id-type="pmid">29273520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41167.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andresen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Layer</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Medical Therapy of Constipation: Current Standards and Beyond.</article-title>
            <source>Visc Med</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>123</fpage>
            <page-range>123-127</page-range>
            <pub-id pub-id-type="pmid">29888241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41167.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farmer</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Holt</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Downes</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Ruggeri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Del Vecchio</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>De Giorgio</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology, diagnosis, and management of opioid-induced constipation.</article-title>
            <source>Lancet Gastroenterol Hepatol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>203</fpage>
            <page-range>203-212</page-range>
            <pub-id pub-id-type="pmid">29870734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41167.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luthra</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Burr</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Brenner</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and network meta-analysis.</article-title>
            <source>Gut</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>68</volume>
            <issue>3</issue>
            <fpage>434</fpage>
            <page-range>434-444</page-range>
            <pub-id pub-id-type="pmid">29730600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41167.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leppert</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>The impact of opioid analgesics on the gastrointestinal tract function and the current management possibilities.</article-title>
            <source>Contemp Oncol (Pozn)</source>
            <year>2012</year>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>125</fpage>
            <page-range>125-31</page-range>
            <pub-id pub-id-type="pmid">23788866</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41167.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robb</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Loe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Maharaj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hamblin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Seddon</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Medication-related patient harm in New Zealand hospitals.</article-title>
            <source>N Z Med J</source>
            <year>2017</year>
            <month>Aug</month>
            <day>11</day>
            <volume>130</volume>
            <issue>1460</issue>
            <fpage>21</fpage>
            <page-range>21-32</page-range>
            <pub-id pub-id-type="pmid">28796769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41167.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zarowitz</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>O'Shea</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Datto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Olufade</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Clinical and Functional Characteristics of Nursing Facility Residents with Opioid-Induced Constipation.</article-title>
            <source>Consult Pharm</source>
            <year>2017</year>
            <month>May</month>
            <day>01</day>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>285</fpage>
            <page-range>285-298</page-range>
            <pub-id pub-id-type="pmid">28483009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41167.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Peechakara</surname>
                <given-names>BV</given-names>
              </name>
              <name>
                <surname>Tharp</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Eriator</surname>
                <given-names>II</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Codeine</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">30252285</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41167.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davis</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>The opioid bowel syndrome: a review of pathophysiology and treatment.</article-title>
            <source>J Opioid Manag</source>
            <year>2005</year>
            <season>Jul-Aug</season>
            <volume>1</volume>
            <issue>3</issue>
            <fpage>153</fpage>
            <page-range>153-61</page-range>
            <pub-id pub-id-type="pmid">17315419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41167.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000fc;ller-Lissner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bassotti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Coffin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Drewes</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Breivik</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Eisenberg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Emmanuel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laroche</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Meissner</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Morlion</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Opioid-Induced Constipation and Bowel Dysfunction: A Clinical Guideline.</article-title>
            <source>Pain Med</source>
            <year>2017</year>
            <month>Oct</month>
            <day>01</day>
            <volume>18</volume>
            <issue>10</issue>
            <fpage>1837</fpage>
            <page-range>1837-1863</page-range>
            <pub-id pub-id-type="pmid">28034973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41167.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Longstreth</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Chey</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Houghton</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Mearin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Spiller</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Functional bowel disorders.</article-title>
            <source>Gastroenterology</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>130</volume>
            <issue>5</issue>
            <fpage>1480</fpage>
            <page-range>1480-91</page-range>
            <pub-id pub-id-type="pmid">16678561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41167.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Faigel</surname>
                <given-names>DO</given-names>
              </name>
            </person-group>
            <article-title>A clinical approach to constipation.</article-title>
            <source>Clin Cornerstone</source>
            <year>2002</year>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>11</fpage>
            <page-range>11-21</page-range>
            <pub-id pub-id-type="pmid">12739323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41167.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Barker</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Emmanuel</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Opioid-induced constipation: pathophysiology, clinical consequences, and management.</article-title>
            <source>Gastroenterol Res Pract</source>
            <year>2014</year>
            <volume>2014</volume>
            <fpage>141737</fpage>
            <pub-id pub-id-type="pmid">24883055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41167.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bharucha</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Pemberton</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Locke</surname>
                <given-names>GR</given-names>
              </name>
            </person-group>
            <article-title>American Gastroenterological Association technical review on constipation.</article-title>
            <source>Gastroenterology</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>144</volume>
            <issue>1</issue>
            <fpage>218</fpage>
            <page-range>218-38</page-range>
            <pub-id pub-id-type="pmid">23261065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41167.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sridharan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sivaramakrishnan</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Drugs for Treating Opioid-Induced Constipation: A Mixed Treatment Comparison Network Meta-analysis of Randomized Controlled Clinical Trials.</article-title>
            <source>J Pain Symptom Manage</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>55</volume>
            <issue>2</issue>
            <fpage>468</fpage>
            <page-range>468-479.e1</page-range>
            <pub-id pub-id-type="pmid">28919541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41167.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mozaffari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nikfar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abdollahi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Methylnaltrexone bromide for the treatment of opioid-induced constipation.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>19</volume>
            <issue>10</issue>
            <fpage>1127</fpage>
            <page-range>1127-1135</page-range>
            <pub-id pub-id-type="pmid">29979903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41167.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zakari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sugarman</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hirsch</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sultan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ballou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Iturrino</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lembo</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Treatments for Opioid-Induced Constipation: Systematic Review and Meta-analysis.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>16</volume>
            <issue>10</issue>
            <fpage>1569</fpage>
            <page-range>1569-1584.e2</page-range>
            <pub-id pub-id-type="pmid">29374616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41167.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chedid</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Camilleri</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Assessing the efficacy of peripherally acting mu-opioid receptor antagonists (PAMORAs) in the treatment of opioid-induced constipation.</article-title>
            <source>Gut</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>68</volume>
            <issue>6</issue>
            <fpage>1133</fpage>
            <page-range>1133-1134</page-range>
            <pub-id pub-id-type="pmid">29884613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41167.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Argoff</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Camilleri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fudin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Galluzzi</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Gudin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lembo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stanos</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Webster</surname>
                <given-names>LR</given-names>
              </name>
            </person-group>
            <article-title>Consensus Recommendations on Initiating Prescription Therapies for Opioid-Induced Constipation.</article-title>
            <source>Pain Med</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>16</volume>
            <issue>12</issue>
            <fpage>2324</fpage>
            <page-range>2324-37</page-range>
            <pub-id pub-id-type="pmid">26582720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41167.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Szigethy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Drossman</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Narcotic bowel syndrome and opioid-induced constipation.</article-title>
            <source>Curr Gastroenterol Rep</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>16</volume>
            <issue>10</issue>
            <fpage>410</fpage>
            <pub-id pub-id-type="pmid">25183577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41167.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saper</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Lake</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Bain</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Stillman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Rothrock</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Mathew</surname>
                <given-names>NT</given-names>
              </name>
              <name>
                <surname>Hamel</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Moriarty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tietjen</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>A practice guide for continuous opioid therapy for refractory daily headache: patient selection, physician requirements, and treatment monitoring.</article-title>
            <source>Headache</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>50</volume>
            <issue>7</issue>
            <fpage>1175</fpage>
            <page-range>1175-93</page-range>
            <pub-id pub-id-type="pmid">20649650</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
